rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Quoin Pharmaceuticals, Ltd. - American Depositary Shares

QNRX · Nasdaq

Health CareBiotechnologyNot moving yet

QNRX stood above a rising 150-day average in 12 of the last 52 weekly readings, and has been out of that trend for the last 40 weeks. It is 29.1% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 40
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$560K
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
19 (-1)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 12 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$578KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months4
Sale orders, 12 months0
Buyers · sellers4 · 0
WhoDidSharesTraded
Anthony James CulverwellDirectorbought6,146at $4.8831 Aug 2026filed 1 Sep 2026
Anthony James CulverwellDirectorbought3,07331 Aug 2026filed 1 Sep 2026
Sally Bridget LawlorChief Financial Officerbought10,244at $4.8831 Aug 2026filed 1 Sep 2026
Sally Bridget LawlorChief Financial Officerbought5,12231 Aug 2026filed 1 Sep 2026
Michael MyersChief Executive Officerbought20,490at $4.8831 Aug 2026filed 1 Sep 2026
Michael MyersChief Executive Officerbought10,24531 Aug 2026filed 1 Sep 2026
Denise P. CarterChief Operating Officerbought20,490at $4.8831 Aug 2026filed 1 Sep 2026
Denise P. CarterChief Operating Officerbought10,24531 Aug 2026filed 1 Sep 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders19-1 on the quarter
New · exited1 · 2
Reported value$7.4M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Stonepine Capital Management, LLCadded · filed 14 Aug 2026765,546$2.0M+712,086+1332.0%
Dauntless Investment Group, LLCadded · filed 13 Aug 2026214,987$1.0M+18,395+9.4%
Ikarian Capital, LLCunchanged · filed 14 Aug 2026211,538$1.0M00.0%
MILLENNIUM MANAGEMENT LLCadded · filed 14 Aug 2026112,323$544K+36,076+47.3%
SummitTX Capital, L.P.unchanged · filed 14 Aug 2026100,300$485K00.0%
Woodline Partners LPreduced · filed 14 Aug 202676,446$370K-3,136−3.9%
Aberdeen Group plcunchanged · filed 31 Jul 202675,000$363K00.0%
Soleus Capital Management, L.P.unchanged · filed 11 Aug 202672,730$352K00.0%
AIGH Capital Management LLCadded · filed 7 Aug 202670,000$339K+19,000+37.3%
BOOTHBAY FUND MANAGEMENT, LLCunchanged · filed 14 Aug 202659,838$290K00.0%
31 Mar 2025 – 30 Jun 2026
21119Mar 25Jun 25Dec 25Mar 26Jun 26

News

No headline names it lately.

Everyone who traded it

Anthony James Culverwell Company insiderDirector · last 31 Aug 20262 · 0
Denise P. Carter Company insiderChief Operating Officer · last 31 Aug 20264 · 0
Michael Myers Company insiderChief Executive Officer · last 31 Aug 20264 · 0
Sally Bridget Lawlor Company insiderChief Financial Officer · last 31 Aug 20261 · 0
Dennis Langer Company insiderDirector · last 27 Aug 20261 · 1
Joseph Patrick Cooper Company insiderDirector · last 4 Feb 20260 · 0
Michael T. Sember Company insiderDirector · last 4 Feb 20260 · 0
Natalie Ee Mun Leong Company insiderDirector · last 4 Feb 20260 · 0
Gordon Dunn Company insiderChief Financial Officer · last 23 Dec 20243 · 0

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Cash and equivalentsFY 2025 · to 31 Dec 2025$3.8M

Analyst forecasts

No analyst forecasts yet.